HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic equivalence of sulfaisodimidine 2 g twice daily and 1 g four times daily in lower urinary tract infections.

Abstract
The serum concentrations and clinical effects of sulfaisodimidine given during 12 days were examined in two groups of patients with uncomplicated lower urinary tract infection. Group I (n=12) received the drug in a conventional dosage, 1 g four times daily, and group II (n=14) in a dose of 2 g twice daily. The serum concentrations of sulfonamide at steady state (day 7) and one day after cessation of therapy (day 13) did not differ significantly between the groups. With the exception of one patient in group I, both subjective and objective symptoms vanished during treatment and remained absent for at least 4 weeks thereafter. Two patients in each group developed signs of sulfonamide allergy. Thus, the two regimens seemed to be equally efficient, and the risk of therapy failure due to low blood concentrations of sulfaisodimidine should not be greater when the drug is given in a dosage of 2 g twice daily than when it is administered in the conventional way. Hence, the latter, simpler regimen can be recommended.
AuthorsA Melander, P O Bitzén, S Olsson
JournalActa medica Scandinavica (Acta Med Scand) Vol. 211 Issue 5 Pg. 361-4 ( 1982) ISSN: 0001-6101 [Print] Sweden
PMID7051761 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Sulfisomidine
Topics
  • Adult
  • Aged
  • Clinical Trials as Topic
  • Drug Hypersensitivity (etiology)
  • Humans
  • Middle Aged
  • Sulfisomidine (administration & dosage, adverse effects, blood)
  • Time Factors
  • Urinary Tract Infections (drug therapy, urine)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: